Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.57 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13911257 | 1.00 | TAAR1 (0.57) | TAAR1AOC3MEN1KMT2ABCHE | |
| SCHEMBL7791795 | 0.89 | TAAR1 (0.53) | TAAR1AOC3MEN1KMT2ABCHE | |
| SCHEMBL11112776 | 0.85 | GRIN1 (0.58) | TAAR1AOC3MEN1KMT2AGRIN1 | |
| SCHEMBL11046082 | 0.85 | TAAR1 (0.68) | TAAR1AOC3MEN1KMT2ABCHE | |
| SCHEMBL20689708 | 0.84 | GRIN1 (0.66) | TAAR1AOC3MEN1KMT2ABCHE | |
| SCHEMBL20689725 | 0.84 | GRIN1 (0.66) | TAAR1AOC3MEN1KMT2ABCHE | |
| SCHEMBL20689710 | 0.84 | GRIN1 (0.66) | TAAR1AOC3MEN1KMT2ABCHE | |
| SCHEMBL4403167 | 0.83 | GRIN1 (0.64) | MEN1KMT2AGRIN1GRIN2ASIGMAR1 | |
| SCHEMBL3430600 | 0.83 | TAAR1 (0.61) | TAAR1AOC3MEN1KMT2ABCHE | |
| SCHEMBL8278973 | 0.83 | TAAR1 (0.61) | TAAR1AOC3MEN1KMT2ABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807646-B2 | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2023-11-07 | — | — | US | disclosed |
| US-20210070773-A1 | 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807646-B2 | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) | USP19, USP16, USP18 | TAAR1 4621/4885AOC3 3332/4885MEN1 4318/4885 |
| US-20210070773-A1 | 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | USP19, USP16, USP18 | TAAR1 4621/4885AOC3 3332/4885MEN1 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.